Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00418574 · ClinicalTrials.gov registry record · Phase 2
Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients
A Phase 2 study, sponsored by Menarini Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 888
- Enrollment target
NCT00418574: Clinical Trial Phase 2 study, sponsored by Menarini Group.
NCT00418574 is a Phase 2 study that was terminated before completion, run by Menarini Group. The registered enrollment target is 888 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (568% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00418574, a Phase 2 study, was terminated before completion, sponsored by Menarini Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 888 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the benefit of vaccination with Abagovomab, an experimental immunotherapy in ovarian cancer patients. The benefit will be evaluated in terms of time the remission status is kept as well as prolongation of life expectancy.
Primary Outcome
The Recurrence free survival correspond to the time from date of randomization to documented disease recurrence or death. Disease recurrence is defined as the appearance of any lesion or development of tumor-related symptoms evaluated by medical examination and must be confirmed by a documented CT scan.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Abagovomab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 888 participants |
| Start Date | 2006-12 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Why NCT00418574 stopped before completion
NCT00418574 is an interventional study that assigns participants to a tested intervention. The registered 888 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (568% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00418574 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00418574 about?
NCT00418574 is a clinical study titled "Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients". The purpose of this study is to evaluate the benefit of vaccination with Abagovomab, an experimental immunotherapy in ovarian cancer patients. The benefit will be evaluated in terms of time the remission status is kept as well as prolongation of life expectancy.
What is the current status of trial NCT00418574?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 888 participants. The study started on 2006-12. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00418574?
The interventions under investigation include: Placebo (BIOLOGICAL), Abagovomab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00418574?
This trial is sponsored by Menarini Group, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00418574's enrollment target sits among peer trials
888 33rd of 2000 higher than 1,968 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03564340 · 890 participants · Phase 1
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- NCT05855200 · 892 participants · Phase 3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
- NCT07196748 · 882 participants · Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- NCT04862663 · 895 participants · Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia